Levosimendan Infusion Dosing
The recommended intravenous infusion dose of levosimendan is an optional loading bolus of 12 μg/kg over 10 minutes, followed by a continuous infusion starting at 0.1 μg/kg/min, which can be decreased to 0.05 or increased to 0.2 μg/kg/min based on response and tolerability, administered for 24 hours. 1, 2, 3
Loading Bolus Considerations
The loading bolus should be omitted in hypotensive patients (systolic blood pressure <100 mmHg) to avoid precipitating further hypotension 1, 2. The 2008 ESC guidelines explicitly state that in patients with SBP <100 mmHg, therapy should be initiated without a bolus dose 2. The earlier 2005 ESC guidelines used a range of 12-24 μg/kg for the bolus 4, but the more recent 2008 and 2016 guidelines standardized this to 12 μg/kg as optional 1, 2, 3.
Infusion Rate Algorithm
- Starting dose: 0.1 μg/kg/min for all patients
- Downward titration: Reduce to 0.05 μg/kg/min if hypotension develops or patient is borderline hypotensive
- Upward titration: Increase to 0.2 μg/kg/min if hemodynamic response is inadequate and blood pressure tolerates
- Duration: Continue for 24 hours
This dosing strategy is consistent across multiple ESC guideline iterations 1, 2, 3.
Clinical Context and Hemodynamic Effects
Levosimendan functions as a calcium sensitizer with vasodilatory properties, making it particularly useful in acute heart failure with low cardiac output 2. The drug increases cardiac output and stroke volume while reducing pulmonary wedge pressure and systemic vascular resistance 2. Research demonstrates dose-dependent hemodynamic improvements, with the 0.1-0.2 μg/kg/min range providing optimal efficacy while maintaining tolerability 5, 6.
Important Caveats
Blood pressure monitoring is critical. Levosimendan causes vasodilation, and hypotension is the primary limiting factor 2. The drug should not be used as monotherapy in patients with SBP <85 mmHg or cardiogenic shock unless combined with vasopressors 3.
Heart rate increases are expected. A slight dose-related increase in heart rate occurs, though typically less pronounced than with catecholamines 2, 7.
Beta-blocker interaction is favorable. Unlike dobutamine, levosimendan's mechanism of action (distal to beta-receptors) means it maintains efficacy in patients on beta-blocker therapy, making it a preferred choice in this population 1, 2, 3.
Comparison to Alternative Dosing
While some research has explored lower continuous infusion rates (0.05 μg/kg/min without bolus for chronic intermittent therapy) 8, and earlier dose-ranging studies evaluated higher rates up to 0.6 μg/kg/min 5, the guideline-endorsed therapeutic window of 0.05-0.2 μg/kg/min represents the optimal balance of efficacy and safety for acute decompensated heart failure 1, 2, 3.
The 2016 ESC guidelines maintain this dosing recommendation as the most current authoritative guidance 3, superseding earlier variations that suggested bolus doses up to 24 μg/kg 4.